Clinical impact of programmed cell death ligand 1 expression in colorectal cancer

European Journal of Cancer

Volumn 49, Issue 9, 2013, Pages 2233-2242

  Droeser, Raoul A ^a,b   Hirt, Christian ^a,b   Viehl, Carsten T ^a   Frey, Daniel M ^a   Nebiker, Christian ^a,b   Huber, Xaver ^a   Zlobec, Inti ^c   Eppenberger Castori, Serenella ^b   Tzankov, Alexander ^b   Rosso, Raffaele ^d   Zuber, Markus ^e   Muraro, Manuele Giuseppe ^b   Amicarella, Francesca ^b   Cremonesi, Eleonora ^b   Heberer, Michael ^b   Iezzi, Giandomenica ^b   Lugli, Alessandro ^c   Terracciano, Luigi ^b   Sconocchia, Giuseppe ^f   Oertli, Daniel ^a   Spagnoli, Giulio C ^b   Tornillo, Luigi ^b   more..

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^e KANTONSSPITAL   (Switzerland)

^f INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

Author keywords

Human colorectal cancer; Overall survival; PD L1; Prognostic factors; Tissue microarrays

Indexed keywords

DEATH RECEPTOR; GAMMA INTERFERON; PROGRAMMED CELL DEATH RECEPTOR 1; PROGRAMMED DEATH 1 LIGAND 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR INVASION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; COLONIC NEOPLASMS; DNA MISMATCH REPAIR; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PROGNOSIS; RECTAL NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84877704099     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.02.015     Document Type: Article

References (49)

1. J. Galon, A. Costes, and F. Sanchez-Cabo Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 2006 1960 1964
2. F. Pages, A. Berger, and M. Camus Effector memory T cells, early metastasis, and survival in colorectal cancer N Engl J Med 353 2005 2654 2666
3. S.J. Khoury, and M.H. Sayegh The roles of the new negative T cell costimulatory pathways in regulating autoimmunity Immunity 20 2004 529 538
4. T. Okazaki, and T. Honjo The PD-1-PD-L pathway in immunological tolerance Trends Immunol 27 2006 195 201
5. T.J. Curiel, S. Wei, and H. Dong Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity Nat Med 9 2003 562 567
6. G.J. Freeman, A.J. Long, and Y. Iwai Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 2000 1027 1034
7. Y. Latchman, C.R. Wood, and T. Chernova PD-L2 is a second ligand for PD-1 and inhibits T cell activation Nat Immunol 2 2001 261 268
8. M.E. Keir, S.C. Liang, and I. Guleria Tissue expression of PD-L1 mediates peripheral T cell tolerance J Exp Med 203 2006 883 895
9. M.E. Keir, M.J. Butte, G.J. Freeman, and A.H. Sharpe PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 2008 677 704
10. T. Shin, K. Yoshimura, and T. Shin In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses J Exp Med 201 2005 1531 1541
11. L. Zhang, T.F. Gajewski, and J. Kline PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model Blood 114 2009 1545 1552
12. F. Hirano, K. Kaneko, and H. Tamura Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Res 65 2005 1089 1096
13. Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, and N. Minato Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proc Natl Acad Sci U S A 99 2002 12293 12297
14. J. Konishi, K. Yamazaki, M. Azuma, I. Kinoshita, H. Dosaka-Akita, and M. Nishimura B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression Clin Cancer Res 10 2004 5094 5100
15. Y. Ohigashi, M. Sho, and Y. Yamada Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer Clin Cancer Res 11 2005 2947 2953
16. S.E. Strome, H. Dong, and H. Tamura B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma Cancer Res 63 2003 6501 6505
17. R.H. Thompson, M.D. Gillett, and J.C. Cheville Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target Proc Natl Acad Sci U S A 101 2004 17174 17179
18. S. Wintterle, B. Schreiner, and M. Mitsdoerffer Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis Cancer Res 63 2003 7462 7467
19. J.R. Brahmer, C.G. Drake, and I. Wollner Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 2010 3167 3175
20. J.R. Brahmer, S.S. Tykodi, and L.Q. Chow Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
21. S.L. Topalian, F.S. Hodi, and J.R. Brahmer Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
22. O.P. Kallioniemi, U. Wagner, J. Kononen, and G. Sauter Tissue microarray technology for high-throughput molecular profiling of cancer Hum Mol Genet 10 2001 657 662
23. G. Sauter, R. Simon, and K. Hillan Tissue microarrays in drug discovery Nat Rev Drug Discov 2 2003 962 972
24. J. Hamanishi, M. Mandai, and M. Iwasaki Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer Proc Natl Acad Sci U S A 104 2007 3360 3365
25. M. Loos, R. Langer, and T. Schuster Clinical significance of the costimulatory molecule B7-H1 in Barrett carcinoma Ann Thorac Surg 91 2011 1025 1031
26. D.M. Frey, R.A. Droeser, and C.T. Viehl High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients Int J Cancer 126 2010 2635 2643
27. I. Zlobec, E. Karamitopoulou, and L. Terracciano TIA-1 cytotoxic granule-associated RNA binding protein improves the prognostic performance of CD8 in mismatch repair-proficient colorectal cancer PLoS One 5 2010 e14282
28. A. Lugli, I. Zlobec, and K. Baker Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status J Clin Pathol 60 2007 534 539
29. K. Baker, I. Zlobec, L. Tornillo, L. Terracciano, J.R. Jass, and A. Lugli Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: a potential role for dysregulation of the transforming growth factor-beta pathway Eur J Cancer 43 2007 624 631
30. C. Feder-Mengus, E. Schultz-Thater, and D. Oertli Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses Hum Gene Ther 16 2005 348 360
31. I. Martin, M. Jakob, D. Schafer, W. Dick, G. Spagnoli, and M. Heberer Quantitative analysis of gene expression in human articular cartilage from normal and osteoarthritic joints Osteoarthritis Cartilage 9 2001 112 118
32. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method Methods 25 2001 402 408
33. R.E. Barlow, D.J. Bartholomew, and J.M. Bremner Statistical inference under order restrictions: theory and application of isotonic regression 1972 John Wiley & Sons Ltd. London
34. L. Breiman, J. Friedman, and C.J. Stone Classification and regression trees 1984 Chapman & Hall/CRC
35. L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark Reporting recommendations for tumor marker prognostic studies (REMARK) J Natl Cancer Inst 97 2005 1180 1184
36. P. Kanavaros, M.L. Boulland, B. Petit, B. Arnulf, and P. Gaulard Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression Leuk Lymphoma 38 2000 317 326
37. J.M. Taube, R.A. Anders, and G.D. Young Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape Sci Transl Med 4 2012 127ra37
38. A. Mantovani, P. Romero, A.K. Palucka, and F.M. Marincola Tumour immunity: effector response to tumour and role of the microenvironment Lancet 371 2008 771 783
39. R.D. Schreiber, L.J. Old, and M.J. Smyth Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion Science 331 2011 1565 1570
40. R.L. Ferris, T.L. Whiteside, and S. Ferrone Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer Clin Cancer Res 12 2006 3890 3895
41. W. Zou Immunosuppressive networks in the tumour environment and their therapeutic relevance Nat Rev Cancer 5 2005 263 274
42. L.M. Francisco, V.H. Salinas, and K.E. Brown PD-L1 regulates the development, maintenance, and function of induced regulatory T cells J Exp Med 206 2009 3015 3029
43. A.T. Parsa, J.S. Waldron, and A. Panner Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma Nat Med 13 2007 84 88
44. D. Pardoll, and C. Drake Immunotherapy earns its spot in the ranks of cancer therapy J Exp Med 209 2012 201 209
45. A.L. Kau, P.P. Ahern, N.W. Griffin, A.L. Goodman, and J.I. Gordon Human nutrition, the gut microbiome and the immune system Nature 474 2011 327 336
46. S. Ladoire, F. Martin, and F. Ghiringhelli Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer Cancer Immunol Immunother 60 2011 909 918
47. P. Salama, M. Phillips, and F. Grieu Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer J Clin Oncol 27 2009 186 192
48. G. Sconocchia, I. Zlobec, and A. Lugli Tumor infiltration by FcgammaRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma Int J Cancer 128 2011 2663 2672
49. C.S. Roxburgh, and D.C. McMillan The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer Cancer Treat Rev 38 2012 451 466